Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Nilotinib treatment-free remission study in chronic phase CML
NL-OMON38639Phase 3Active, not recruiting
- Sponsor
- Novartis
- Start
- Oct 2013
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, open-label trial of nilotinib in chronic myelogenous leukemia (CML), sponsored by Novartis. Started Oct 2013; status: active, not recruiting.
02
Drugs
nilotinib
03
Conditions
chronic myelogenous leukemia (CML)
Beyond the preview
Go deeper on NL-OMON38639.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON38639.